Abd-Elsalam S - Search Results

1

Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.

Medhat MA, El-Kassas M, Karam-Allah H, Al Shafie A, Abd-Elsalam S, Moustafa E, Hassany SM, Salama M, Abd Elghafar MS, Sayed H, Badr M, Kamal DT, Shamseldeen A, Ossimi A, Moaz I, Esmael HE, Ezz Eldin AM, Ezzat S, Abdelghaffar H, Abdelghaffar K. Medhat MA, et al. Arab J Gastroenterol. 2022 Aug;23(3):165-171. doi: 10.1016/j.ajg.2022.04.005. Epub 2022 May 6. Arab J Gastroenterol. 2022. PMID: 35690556 Free PMC article. Clinical Trial.

2

Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.

Ahmed OA, Kaisar HH, Hawash N, Samir H, Shabana SST, Hassan A Fouad M, Rizk F, Abd-Elsalam S. Ahmed OA, et al. Infect Disord Drug Targets. 2017;17(2):95-100. doi: 10.2174/1871526517666170417143216. Infect Disord Drug Targets. 2017. PMID: 28413993 Clinical Trial.

3

Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection.

Shehata MA, Talaat R, Soliman S, Elmesseri H, Soliman S, Abd-Elsalam S. Shehata MA, et al. Helicobacter. 2017 Oct;22(5). doi: 10.1111/hel.12395. Epub 2017 May 19. Helicobacter. 2017. PMID: 28524341 Clinical Trial.

4

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.

Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Abd-Elsalam S, et al. Arch Virol. 2018 Jan;163(1):51-56. doi: 10.1007/s00705-017-3573-0. Epub 2017 Oct 5. Arch Virol. 2018. Retraction in: Arch Virol. 2022 Nov;167(11):2441. doi: 10.1007/s00705-022-05600-w PMID: 28983675 Retracted.

5

Epidemiology of liver cancer in Nile delta over a decade: A single-center study.

Abd-Elsalam S, Elwan N, Soliman H, Ziada D, Elkhalawany W, Salama M, Hawash N, Arafa M, Badawi R, Shehata WM, Khalil HS, Elmashad N. Abd-Elsalam S, et al. South Asian J Cancer. 2018 Jan-Mar;7(1):24-26. doi: 10.4103/sajc.sajc_82_17. South Asian J Cancer. 2018. PMID: 29600229 Free PMC article.

6

A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy.

Abd-Elsalam S, El-Kalla F, Elwan N, Badawi R, Hawash N, Soliman S, Soliman S, Elkhalawany W, ElSawaf MA, Elfert A. Abd-Elsalam S, et al. J Clin Gastroenterol. 2019 Mar;53(3):226-230. doi: 10.1097/MCG.0000000000001040. J Clin Gastroenterol. 2019. PMID: 29668561 Clinical Trial.

7

Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.

Abd-Elsalam S, Badawi R, Elnawasany S, Yousef M, Mansour L, Hawash N, Elkhouly RA, Soliman S, Selim A, Kobtan A, Elfert A. Abd-Elsalam S, et al. Infect Disord Drug Targets. 2019;19(2):179-184. doi: 10.2174/1871526518666180912121835. Infect Disord Drug Targets. 2019. PMID: 30207250 Clinical Trial.

8

Diabetes Association with Liver Diseases: An Overview for Clinicians.

Hamed AE, Elwan N, Naguib M, Elwakil R, Esmat G, El Kassas M, Abd-Elsalam S, Moussa S. Hamed AE, et al. Endocr Metab Immune Disord Drug Targets. 2019;19(3):274-280. doi: 10.2174/1871530318666181116111945. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30444204 Review.

9

Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection.

Ahmed OA, Elsebaey MA, Fouad MHA, Elkadeem M, Badawi R, Khayyal A, Soliman S, Negm MS, Abd-Elsalam S. Ahmed OA, et al. Infect Disord Drug Targets. 2020;20(3):389-395. doi: 10.2174/1871526519666181218104600. Infect Disord Drug Targets. 2020. PMID: 30569878

10

Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt.

Badawi R, Alboraie M, Abd-Elsalam S, Abourahma MZ, Ramadan HK, Ahmed OA, Fouad MHA, Soliman S, Mohareb DA, Haydara T, Alnabawy SM, El Kassas M. Badawi R, et al. Endocr Metab Immune Disord Drug Targets. 2019;19(7):1005-1011. doi: 10.2174/1871530319666190204154830. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30727931 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters